Literature DB >> 27690258

Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin.

Daniela Belletti1, Francesca Pederzoli1, Flavio Forni1, Maria Angela Vandelli1, Giovanni Tosi1, Barbara Ruozi1.   

Abstract

INTRODUCTION: New frontiers in nanomedicine are moving towards the research of new biomaterials. Apoferritin (APO), is a uniform regular self-assemblies nano-sized protein with excellent biocompatibility and a unique structure that affords it the ability to stabilize small active molecules in its inner core. Areas covered: APO can be loaded by applying a passive process (mainly used for ions and metals) or by a unique formulative approach based on disassemby/reassembly process. In this article, we aim to organize the experimental evidence provided by a number of studies on the loading, release and targeting. Attention is initially focused on the most investigated antineoplastic drug and contrast agents up to the most recent application in gene therapy. Expert opinion: Various preclinical studies have demonstrated that APO improved the potency and selectivity of some chemotherapeutics. However, in order to translate the use of APO into therapy, some issues must be solved, especially regarding the reproducibility of the loading protocol used, the optimization of nanocarrier characterization, detailed understanding of the final structure of loaded APO, and the real mechanism and timing of drug release.

Entities:  

Keywords:  Apoferritin; chemotherapeutics; disassembly/reassembly; nano-cage; passive loading; structural characterization

Mesh:

Substances:

Year:  2016        PMID: 27690258     DOI: 10.1080/17425247.2017.1243528

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  10 in total

Review 1.  Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.

Authors:  Mahdi Karimi; Parham Sahandi Zangabad; Fatemeh Mehdizadeh; Hedieh Malekzad; Alireza Ghasemi; Sajad Bahrami; Hossein Zare; Mohsen Moghoofei; Amin Hekmatmanesh; Michael R Hamblin
Journal:  Nanoscale       Date:  2017-01-26       Impact factor: 7.790

Review 2.  Bioengineered Ferritin Nanocarriers for Cancer Therapy.

Authors:  Xuanrong Sun; Yulu Hong; Yubei Gong; Shanshan Zheng; Dehui Xie
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

3.  Development of novel apoferritin formulations for antitumour benzothiazoles.

Authors:  Alastair F Breen; Geoffrey Wells; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-16

4.  In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy.

Authors:  Kelong Fan; Juqun Xi; Lei Fan; Peixia Wang; Chunhua Zhu; Yan Tang; Xiangdong Xu; Minmin Liang; Bing Jiang; Xiyun Yan; Lizeng Gao
Journal:  Nat Commun       Date:  2018-04-12       Impact factor: 14.919

5.  GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy.

Authors:  Bing Jiang; Ruofei Zhang; Jianlin Zhang; Yaxin Hou; Xuehui Chen; Meng Zhou; Xiuyun Tian; Chunyi Hao; Kelong Fan; Xiyun Yan
Journal:  Theranostics       Date:  2019-04-12       Impact factor: 11.556

6.  High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.

Authors:  Elisabetta Falvo; Verena Damiani; Patrizio Giacomini; Michele Milella; Vincenzo De Laurenzi; Giulio Fracasso; Pierpaolo Ceci; Giamaica Conti; Federico Boschi; Katia Messana; Veronica Morea; Gianluca Sala
Journal:  J Exp Clin Cancer Res       Date:  2021-02-10

7.  Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.

Authors:  Simona Dostalova; Hana Polanska; Marketa Svobodova; Jan Balvan; Olga Krystofova; Yazan Haddad; Sona Krizkova; Michal Masarik; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Vojtech Adam
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

8.  Questions about horse spleen ferritin crossing the blood brain barrier via mouse transferrin receptor 1.

Authors:  Kelong Fan; Meng Zhou; Xiyun Yan
Journal:  Protein Cell       Date:  2017-11       Impact factor: 14.870

Review 9.  Ferritins as natural and artificial nanozymes for theranostics.

Authors:  Bing Jiang; Long Fang; Kongming Wu; Xiyun Yan; Kelong Fan
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

10.  Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.

Authors:  Alastair F Breen; David Scurr; Maria Letizia Cassioli; Geoffrey Wells; Neil R Thomas; Jihong Zhang; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Int J Nanomedicine       Date:  2019-12-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.